Money is pouring into the fledgling psychedelic medicine industry, with dozens of startup companies vying to be among the first to sell mind-expanding drugs for depression, addiction and other mental health conditions.
Dozens of drug makers have lost their bid to keep a group of price-fixing lawsuits joined together in Pennsylvania federal court, after a court panel said Connecticut and other state plaintiffs could press their own cases separately.